Skip to main content

Table 3 Hazard ratios of joint ER and PR tumors per 5 cm increase in BMI across each age band among all women and never users of HRT.

From: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

 

≤49

years

Between

50 and 54 years

Between

55 and 59 years

Between

60 and 64 years

≥65

years

 

Cases

HR

95%CI

Cases

HR

95%CI

Cases

HR

95%CI

Cases

HR

95%CI

Cases

HR

95%CI

All women

              

Age and center stratified

              

ER+PR+

390

0.79

(0.68-0.91)

698

0.88

(0.79-0.97)

830

1.08

(0.69-1.06)

806

1.05

(0.96-1.14)

862

1.25

(1.16-1.34)

ER+PR-

64

1.10

(0.81-1.50)

180

0.86

(0.69-1.06)

306

0.86

(0.68-1.38)

280

0.86

(0.74-1.01)

256

0.92

(0.78-1.08)

ER-PR+

71

0.68

(0.47-0.99)

57

0.97

(0.68-1.38)

37

0.55

(0.91-1.27)

31

0.83

(0.50-1.37)

17

0.70

(0.35-1.42)

ER-PR-

147

0.89

(0.72-1.12)

217

1.08

(0.91-1.27)

244

0.98

(0.93-1.13)

217

0.95

(0.80-1.12)

196

0.95

(0.79-1.13)

ER or PR missing

533

0.92

(0.82-1.03)

618

1.03

(0.93-1.13)

734

1.03

(1.00-1.18)

731

1.02

(0.94-1.11)

1008

1.09

(1.01-1.17)

P heterogeneity 2

  

0.36

  

0.05

  

0.26

  

0.28

  

0.004

Multivariable model 4

              

ER+PR+

390

0.80

(0.69-0.93)

698

0.90

(0.81-1.01)

830

1.11

(1.01-1.21)

806

1.10

(1.01-1.20)

862

1.32

(1.22-1.43)

ER+PR-

64

1.14

(0.83-1.55)

180

0.90

(0.72-1.12)

306

0.90

(0.76-1.05)

280

0.88

(0.75-1.03)

256

0.97

(0.82-1.14)

ER-PR+

71

0.67

(0.46-0.99)

57

0.98

(0.68-1.40)

37

0.57

(0.32-1.01)

31

0.84

(0.50-1.43)

17

0.79

(0.37-1.68)

ER-PR-

147

0.90

(0.71-1.13)

217

1.09

(0.92-1.29)

244

1.00

(0.84-1.18)

217

0.97

(0.81-1.16)

196

0.97

(0.81-1.17)

ER or PR missing

533

0.93

(0.83-1.05)

618

1.08

(0.98-1.19)

734

1.08

(0.99-1.18)

731

1.06

(0.97-1.16)

1008

1.13

(1.05-1.22)

P heterogeneity 2

  

0.44

  

0.08

  

0.29

  

0.20

  

0.002

HRT never users

              

Age and center stratified

              

ER+PR+

      

350

1.10

(0.97-1.25)

348

1.08

(0.96-1.22)

441

1.34

(1.22-1.47)

ER+PR-

      

135

0.87

(0.69-1.10)

118

0.95

(0.76-1.19)

138

0.96

(0.78-1.18)

ER-PR+

      

16

0.63

(0.28-1.40)

10

0.74

(0.30-1.79)

8

0.98

(0.42-2.29)

ER-PR-

      

95

1.12

(0.88-1.42)

90

1.05

(0.83-1.33)

105

1.06

(0.85-1.32)

ER or PR missing

      

304

1.06

(0.94-1.21)

325

1.08

(0.96-1.22)

566

1.13

(1.03-1.24)

P heterogeneity 2

        

0.94

  

0.83

  

0.05

Multivariable model 5

              

ER+PR+

      

350

1.11

(0.97-1.27)

348

1.13

(1.00-1.28)

441

1.38

(1.25-1.52)

ER+PR-

      

135

0.91

(0.72-1.15)

118

0.96

(0.76-1.21)

138

1.02

(0.83-1.25)

ER-PR+

      

16

0.62

(0.26-1.49)

10

0.63

(0.24-1.67)

8

1.06

(0.37-3.03)

ER-PR-

      

95

1.19

(0.93-1.54)

90

1.09

(0.85-1.40)

105

1.11

(0.88-1.39)

ER or PR missing

      

304

1.09

(0.96-1.24)

325

1.11

(0.98-1.25)

566

1.17

(1.06-1.28)

P heterogeneity 2

        

0.62

  

0.83

  

0.08

  1. 1Per 5 kg/m2 increase; 2heterogeneity between ER+PR+ versus ER-PR- tumors using data augmentation method as described by Lunn and McNeil; 3multivariable hazard ratios were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, age at menarche, menopausal status, age at menopause (in postmenopausal women), ever OC use and current HRT use; 4multivariable hazard ratios were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, age at menarche, ever OC use, menopausal status, age at menopause (in postmenopausal women). BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy; PR, progesterone receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us